Randomized phase II study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia

Key points – This randomized Phase 2 showed obinutuzumab monotherapy demonstrates an increased ORR with 2000-mg over 1000-mg, but no difference in PFS. No meaningful difference was observed in the overall safety profile across the two treatment arms.